-
OncoTargets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Multiple roles and therapeutic implications of Akt signaling in cancer
Review
(3577) Views (1076) Full article downloads
Authors:
Emiliano Calvo, Victoria Bolós, Enrique Grande
Published Date June 2009
Volume 2009:2 Pages 135 - 150
DOI: http://dx.doi.org/10.2147/OTT.S4943
Emiliano Calvo1, Victoria Bolós2, Enrique Grande2
1Centro Integral Oncológico Clara Campal (CiOCC), Madrid. Spain; 2Pfizer Oncology, Alcobendas-Madrid, Spain
Abstract: The prominence of the PI3K-Akt signaling pathway in several tumors indicates a relationship with tumor grade and proliferation. Critical cellular processes are driven through this pathway. More detailed knowledge of the pathogenesis of tumors would enable us to design targeted drugs to block both membrane tyrosine kinase receptors and the intracellular kinases involved in the transmission of the signal. The newly approved molecular inhibitors sunitinib (an inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and other tyrosine kinase receptors), sorafenib (a serine–threonine kinase inhibitor that acts against B-Raf) and temsirolimus (an mTOR inhibitor) shown clinical activity in advanced kidney cancer. Chronic myeloid leukemia has changed its natural history thanks to imatinib and dasatinib, both of which inhibit the intracellular bcr/abl protein derived from the alteration in the Philadelphia chromosome. Intracellular pathways are still important in cancer development and their blockade directly affects outcome. Cross-talk has been observed but is not well understood. Vertical and horizontal pathway blockade are promising anticancer strategies. Indeed, preclinical and early clinical data suggest that combining superficial and intracellular blocking agents can synergize and leverage single-agent activity. The implication of the Akt signaling pathway in cancer is well established and has led to the development of new anticancer agents that block its activation.
Keywords: Akt, cancer, therapeutic target, Akt inhibitors
Other articles by Dr Victoria Bolos
The dual kinase complex FAK-Src as a promising therapeutic target in cancer- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Intranet access to all Dove journals
If you would like your institutional intranet to have access to the Dove Medical Press journals please contact me.
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Topotecan in the treatment of relapsed small cell lung cancer
- Role of trabectedin in the treatment of soft tissue sarcoma




